Company intelligence / Profile preview
Jina Pharmaceuticals, Inc.
Libertyville, Illinois, USAjinapharma.com ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Other
01
Overview
Jina Pharmaceuticals develops innovative therapies using advanced drug delivery platforms. Its lead asset, Endoxifen, has reached Phase III trials for bipolar disorder in the US as of March 2024. The company also has programs in breast cancer and organ transplantation with a focus on improving treatment efficacy and reducing side effects through proprietary formulation technologies. Some products have achieved approval outside the US.
- Therapeutic areas
- OncologyImmunologyPsychiatryDermatology
- Modalities
- Small moleculesLipid-based formulations (e.g., Nanoaqualip platform)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Intas Pharmaceuticals (co-developer of Endoxifen)National Cancer Institute USA involved as developer/collaborator for Endoxifen clinical studies.
Beyond the preview
Go deeper on Jina Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jina Pharmaceuticals, Inc..